January 13, 2010 โ€“ Diagnostic cardiac monitor company Cardiac Science is working to connect its devices with MEDENT's electronic medical record (EMR) system.

January 13, 2010 โ€“ Transcatheter heart valve development company CardiAQ Valve Technologies (CVT) closed a $6.5 million funding deal to clinically validate its technology and carry the company through initial first-in-man studies.

January 12, 2010 โ€“ In its January issue, Prevention magazine named the Endo-PAT2000 endothelial function testing device one of the top medical breakthroughs of 2009.

January 2, 2010 โ€“ The FDA cleared the Celsius RMT ThermoCool ablation catheter for use with Stereotaxis' magnetic navigation system in the treatment of type 1 atrial flutter.

January 11, 2010 โ€“ Health Canada, the Canadian equivalent of the U.S. FDA, cleared heart sound analysis software that connects wirelessly to a Bluetooth-enabled electronic stethoscope.

January 11, 2010 โ€“ A hypertension drug using a combination of telmisartan/amlodipine, which requires less-frequent dosing than Novartis's Diovan/Tareg (valsartan), may earn 30 percent patient share according to surveyed U.S. cardiologists. Similarly, in Europe, the agent would earn comparable patient share of 25 percent according to surveyed European cardiologists.

January 11, 2010 โ€“ The first patients were enrolled in the phase 3 clinical trials for a drug designed to lower triglycerides for patients at risk for cardiovascular disease.

January 8, 2010 โ€“ Transradial angiography leads to reduced patient complications, faster recovery time and decreased hospital costs, according to cardiologists at the University of Illinois at Chicago (UIC) and Jesse Brown VA medical centers. They are among the first in the Chicago area to offer the new approach to heart angiograms and clearing blocked arteries.

January 8, 2010 โ€“ Japanese regulatory officials this week cleared the XIENCE V Everolimus-Eluting Coronary Stent. Abbott said it plans to launch sales in Japan in the coming weeks, immediately following final reimbursement authorization.

January 7, 2010 โ€“ Doctors with Virginia Interventional and Vascular Associates (VIVA) report success in treating acute deep vein thrombosis (DVT) with a procedure called isolated pharmacomechanical thrombolysis (IPMT). The treatment has been used for the past two years to destroy clots much faster than traditional therapies.

Subscribe to
ยฉ Copyright Wainscot Media. All Rights Reserved.
Subscribe Now